News | September 28, 2010

Device to Treat Refractory Angina Featured in Live Case at TCT


September 28, 2010 – The Transcatheter Cardiovascular Therapeutics (TCT) 2010 symposium featured a live case broadcast of a physician implanting a new device to treat refractory angina.

At the Antwerp Cardiovascular Institute/ZNA Middelheim in Belgium, Stefan Verheye, M.D., successfully implanted the Neovasc Reducer in the patient’s coronary sinus. Verheye is the principal investigator in the COSIRA study, designed to assess the efficacy of Neovasc’s implantable Reducer device as a treatment for refractory angina.

Refractory angina is a painful and debilitating condition that occurs when the coronary arteries deliver an inadequate blood supply to the heart muscle.

The reducer is implanted in the coronary sinus vein using a minimally invasive percutaneous procedure that is similar to implanting a coronary stent and takes about 20 minutes. It is intended to provide relief by altering blood flow to the coronary sinus, thereby increasing perfusion of oxygenated blood to certain areas of the heart muscle

For more information: www.neovasc.com


Related Content

News | Cardiovascular Clinical Studies

April 22, 2024 — Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, welcomes the ...

Home April 22, 2024
Home
News | Cardiovascular Clinical Studies

April 16, 2024 — CVRx, Inc., a commercial-stage medical device company, announced today the availability of additional ...

Home April 16, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 — Transcatheter aortic valve replacement (TAVR) was found to bring no increased risks and was associated ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 — People with a buildup of fatty atherosclerotic plaque in the heart’s arteries considered at risk of ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Patients who took an angiotensin-converting enzyme (ACE) inhibitor while undergoing cancer treatment ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — One of the first studies to attempt to treat early-stage heart failure in patients with Type 2 diabetes ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — The investigational drug ninerafaxstat showed a good tolerability and safety profile, along with ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Administering tranexamic acid (TxA), a drug used to reduce bleeding during heart surgery, topically ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Using a web application to qualify individuals for treatment with a nonprescription statin closely ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — People with a small aortic annulus, a part of the heart’s anatomy where the left ventricle meets the ...

Home April 09, 2024
Home
Subscribe Now